Abstract
Background: Pulmonary sarcoidosis is typically diagnosed via endobronchial ultrasound-guided transbronchial needle aspirate (EBUS-TBNA) of hilar and mediastinal lymph nodes to identify non-caseating granulomatous inflammation. Current clinical guidelines do not specify which lymph node stations optimize diagnostic yield, and it remains unclear if yield differs between hilar and mediastinal locations.
Methods: A retrospective study of 225 patients with suspected sarcoidosis was conducted to compare the diagnostic yield of EBUS-TBNA for non-caseating granulomas between hilar and mediastinal nodes.
Results: The diagnostic yield was 61.8% for hilar nodes and 65.5% for mediastinal nodes (P = 0.46). Sensitivity was 66.9% for hilar and 71.1% for mediastinal nodes, while specificity was 100% for both. Multivariable analysis identified age as the only significant predictor of yield (OR 0.96; P < 0.01).
Conclusions: Diagnostic yield is similar across hilar and mediastinal stations, suggesting that node location should not be the primary determinant in sampling strategy.
Introduction
Sarcoidosis is a multisystem inflammatory disease characterized by the formation of non-caseating granulomas. In the thoracic cavity, these granulomas frequently manifest as lymphadenopathy in the mediastinal and hilar regions. To confirm a diagnosis and rule out alternative pathologies such as malignancy or infection, clinicians rely on EBUS-TBNA to obtain tissue samples.
While mediastinal nodes (Stations 2, 4, and 7) are often larger and more accessible than hilar nodes (Stations 10, 11, and 12), there is a lack of consensus regarding whether one region provides a superior diagnostic yield. This study evaluates whether the anatomical location of the sampled lymph node significantly impacts the probability of a successful sarcoidosis diagnosis.
Methods
Researchers at Duke University performed a retrospective analysis of 225 patients who underwent EBUS-TBNA for suspected sarcoidosis between 2015 and 2021. The cohort was diverse, comprising 44.9% African American and 48.4% Caucasian patients, with a female majority (61.3%).
Lymph node stations were categorized according to the International Association for the Study of Lung Cancer (IASLC) map. A total of 144 hilar nodes and 255 mediastinal nodes were analyzed. To ensure statistical accuracy, the team utilized a Generalized Estimating Equation (GEE) model, which accounts for the correlation between multiple nodes sampled from the same patient. Most procedures included Rapid On-Site Evaluation (ROSE) by a cytopathologist to assess sample adequacy in real-time.
Key Results
Diagnostic Yield and Sensitivity
The study found no statistically significant difference in the performance of EBUS-TBNA between the two regions:
- Diagnostic Yield: 61.8% (Hilar) vs. 65.5% (Mediastinal), P = 0.46.
- Sensitivity: 66.9% (Hilar) vs. 71.1% (Mediastinal).
- Specificity: 100% for both locations.
When evaluating yield at the patient level, those who underwent both hilar and mediastinal biopsies had a yield of 73.1%, compared to 71.4% for hilar-only and 67% for mediastinal-only (P=0.63). This suggests that while sampling both regions may marginally increase the chance of diagnosis, the location itself is not a primary driver of success.
Predictors of Success
Interestingly, node size did not correlate with diagnostic success. Although mediastinal nodes were significantly larger than hilar nodes (median 18mm vs. 12mm), the larger size did not result in a higher yield. Similarly, the gauge of the needle used (19G vs. 21G or 22G) had no significant impact on the results.
In the multivariable logistic regression analysis, age was the only factor significantly associated with diagnostic yield (OR 0.96; 95% CI 0.94-0.98; P < 0.01). For every year of increased age, the odds of obtaining a positive biopsy decreased slightly, potentially reflecting the higher disease activity often seen in younger patients.
Discussion
The findings suggest that for clinicians performing EBUS-TBNA in suspected sarcoidosis, the choice between hilar and mediastinal sampling can be guided by technical ease and safety rather than a perceived difference in diagnostic yield.
A notable aspect of the study was the use of ROSE. In clinical practice, a "stopping rule" is often applied: once a positive sample is identified via ROSE, further sampling may be halted to minimize procedural risk. This practice may explain why not all patients had both regions sampled and highlights the efficiency of real-time evaluation in the bronchoscopy suite.
Limitations and Conclusion
This study is limited by its retrospective nature and its status as a single-center trial. The reliance on ROSE may also introduce selection bias regarding which nodes were sampled.
In conclusion, the diagnostic yield of EBUS-TBNA for sarcoidosis is comparable between hilar and mediastinal lymph nodes. Clinicians should prioritize the most accessible nodes and consider that younger patient age is a more reliable predictor of diagnostic success than node location or size. Future prospective, multi-center studies are recommended to further refine sampling guidelines.
Summary updated